Pamela Katkin
Physician Assistant · New York, NYNPI 1457518094
Payments from drug & device makers
Across 468 payments — averaging $31.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AbbVie$1K
- Xeris Pharmaceuticals, Inc.$708
- AstraZeneca$675
- plus $7K from 37 others
What the payments were for
- Food & beverage$14,58499%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,745 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 75 | $87,575 |
| OzempicSemaglutide | 68 | $76,706 |
| JardianceEmpagliflozin | 33 | $33,499 |
| FarxigaDapagliflozin Propanediol | 21 | $22,818 |
| RybelsusSemaglutide | 12 | $15,152 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $11,260 |
| SynthroidLevothyroxine Sodium | 48 | $4,721 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $1,991 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $1,588 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,365 |
| Levothyroxine Sodium | 57 | $586 |
| Metformin Hcl ErMetformin Hcl | 33 | $458 |
| Metformin Hcl | 32 | $358 |
| Methimazole | 14 | $148 |
| Glipizide ErGlipizide | 14 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,920 | $91,85880 claims |
| Lilly USA, LLCMounjaro | $1,504 | $87,57575 claims |
| Boehringer IngelheimJardiance | $374 | $33,49933 claims |
| AstraZenecaFarxiga | $675 | $22,81821 claims |
| AbbVieSynthroid | $1,042 | $4,72148 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $252 | $58657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in New York
- Kristyl Cuenca-SiskoNew York$478K
- Cameron KiserNew York$225K
- Mervat FalahNew York$143K
- Marlene TaylorNew York$109K
- Natalie TafelNew York$77K
- Edwin CalderonNew York$59K
- Jonathan YehNew York$57K
- Emily ElbogenNew York$49K
- Jaclyn ChurchillNew York$48K
- Russell BrandweinNew York$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.